Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials

Journal of Thrombosis and Thrombolysis

Volumn 40, Issue 3, 2015, Pages 317-322

  Angiolillo, Dominick J ^a   Bhatt, Deepak L ^b   Steg, Ph Gabriel ^c,d   Stone, Gregg W ^e   White, Harvey D ^f   Gibson, C Michael ^g   Hamm, Christian W ^h   Price, Matthew J ⁱ   Prats, Jayne ^j   Liu, Tiepu ^j   Mahaffey, Kenneth W ^k   Harrington, Robert A ^k  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

^e NewYork Presbyterian Hospital   (United States)

^f AUCKLAND CITY HOSPITAL   (New Zealand)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h KERCKHOFF HEART CENTER   (Germany)

ⁱ SCRIPPS CLINIC   (United States)

^j MEDICINES COMPANY   (United States)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Antiplatelet; Cangrelor; Overdosing; PCI

Indexed keywords

CANGRELOR; CLOPIDOGREL; PLACEBO; ADENOSINE PHOSPHATE;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DYSPNEA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RETROPERITONEAL HEMORRHAGE; RISK REDUCTION; STABLE ANGINA PECTORIS; THORAX PAIN; THROMBOSIS; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; HEMORRHAGE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL;

ADENOSINE MONOPHOSPHATE; DRUG OVERDOSE; FEMALE; HEMORRHAGE; HUMANS; MALE; PERCUTANEOUS CORONARY INTERVENTION;

EID: 84940438560     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-015-1233-3     Document Type: Article

References (27)

1. Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM, Pollack C, Gibler WB, Ohman EM, Peterson ED (2005) CRUSADE Investigators. excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294(24):3108–3116
2. Mehran R, Pocock SJ, Stone GW, Clayton TC, Dangas GD, Feit F, Manoukian SV, Nikolsky E, Lansky AJ, Kirtane A, White HD, Colombo A, Ware JH, Moses JW, Ohman EM (2009) Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 30(12):1457–1466
3. Chhatriwalla AK, Amin AP, Kennedy KF, House JA, Cohen DJ, Rao SV, Messenger JC, Marso SP (2013) National Cardiovascular Data Registry. Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. JAMA 309(10):1022–1029
4. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114(8):774–782
5. Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Schömig A, Kastrati A (2008) Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 51(7):690–697
6. Halim SA, Rao SV (2011) Bleeding and acute coronary syndromes: defining, predicting, and managing risk and outcomes. Curr Drug Targets 12(12):1831–1835
7. Rao SV, Cohen MG, Kandzari DE, Bertrand OF, Gilchrist IC (2010) The transradial approach to percutaneous coronary intervention: historical perspective, current concepts, and future directions. J Am Coll Cardiol 55(20):2187–2195
8. Franchi F, Angiolillo DJ (2015) Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol 12(1):30–47
9. Angiolillo DJ, Schneider DJ, Bhatt DL, French WJ, Price MJ, Saucedo JF, Shaburishvili T, Huber K, Prats J, Liu T, Harrington RA, Becker RC (2012) Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis 34(1):44–55
10. Franchi F, Rollini F, Muñiz-Lozano A, Cho JR, Angiolillo DJ (2013) Cangrelor: a review on pharmacology and clinical trial development. Expert Rev Cardiovasc Ther 11(10):1279–1291
11. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV Jr, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA, CHAMPION PLATFORM Investigators (2009) Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 361(24):2330–2341
12. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV Jr, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Parikh KH, Skerjanec S, Bhatt DL (2009) Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 361(24):2318–2329
13. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimský P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Généreux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA, CHAMPION PLATFORM Investigators (2013) Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 368(14):1303–1313
14. Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS, Gruberg L, French WJ, White HD, Harrington RA, CHAMPION PLATFORM Investigators (2013) Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 382(9909):1981–1992
15. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500143294.pdf Accessed 29 Mar 2014
16. The GUSTO investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329(10):673–682
17. Antman EM, Morrow DA, McCabe CH, Jiang F, White HD, Fox KA, Sharma D, Chew P, Braunwald E, ExTRACT-TIMI 25 Investigators (2005) Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the enoxaparin and thrombolysis reperfusion for acute myocardial infarction treatment-thrombolysis in myocardial infarction study 25 (ExTRACT-TIMI 25). Am Heart J 149(2):217–226
18. Stone GW, Bertrand M, Colombo A, Dangas G, Farkouh ME, Feit F, Lansky AJ, Lincoff AM, Mehran R, Moses JW, Ohman M, White HD (2004) Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J 148(5):764–775
19. Cavender MA, Rao SV (2010) Bleeding associated with current therapies for acute coronary syndrome: what are the mechanisms? J Thromb Thrombolysis 30(3):332–339
20. Capodanno D, Angiolillo DJ (2010) Antithrombotic therapy in the elderly. J Am Coll Cardiol 56(21):1683–1692
21. Capodanno D, Angiolillo DJ (2012) Antithrombotic therapy in patients with chronic kidney disease. Circulation 125(21):2649–2661
22. Wang TY, Angiolillo DJ, Cushman M, Sabatine MS, Bray PF, Smyth SS, Dauerman HL, French PA, Becker RC (2012) Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. J Am Coll Cardiol 59(10):891–900
23. Capodanno D, Angiolillo DJ (2010) Impact of race and gender on antithrombotic therapy. Thromb Haemost 104(3):471–484
24. Cattaneo M, Schulz R, Nylander S (2014) Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol 63(23):2503–2509
25. Welsh RC, Rao SV, Zeymer U, Thompson VP, Huber K, Kochman J, McClure MW, Gretler DD, Bhatt DL, Gibson CM, Angiolillo DJ, Gurbel PA, Berdan LG, Paynter G, Leonardi S, French WJ, Harrington RA, INNOVATE-PCI Investigators (2012) A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv 5(3):336–346
26. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Ophuis TO, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators (2015) Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med
27. Green CL, Whellan DJ, Lambe L, Bellibas SE, Wijngaard P, Prats J, Krucoff MW (2013) Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: a randomized, double-blind, placebo- and moxifloxacin-controlled thorough QT study. J Cardiovasc Pharmacol 62(5):466–478